Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q4 FY26 results · Jan–Mar 2026
Suven Life Sciences reported revenue from operations of ₹1.52 crore (up 3.6% from Q4 FY25) and net loss of ₹45.60 crore for Q4 FY26 (Jan–Mar 2026), on a consolidated basis.
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.52 | 1.47 | +3.6% | 2.81 | −45.9% |
| Other income | 6.78 | 1.22 | +454.4% | 2.77 | +144.3% |
| Total income | 8.30 | 2.69 | +208.5% | 5.58 | +48.6% |
| Profit before tax | (45.60) | (43.94) | Loss widened | (101.92) | Loss narrowed |
| Net profit for the period | (45.60) | (43.94) | Loss widened | (101.92) | Loss narrowed |
| EPS, basic (₹) | (2.02) | (2.02) | not comparable | (4.55) | not comparable |
| Net margin (%) | -2999.5 | -2995.6 | -3628.8 |
| Item | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1.52 | 1.47 | +3.6% | 2.81 | −45.9% |
| Other income | 6.78 | 1.19 | +469.2% | 2.77 | +145.0% |
| Total income | 8.30 | 2.66 | +212.2% | 5.57 | +48.9% |
| Profit before tax | (11.17) | (15.07) | Loss narrowed | (13.47) | Loss narrowed |
| Net profit for the period | (11.17) | (15.07) | Loss narrowed | (13.47) | Loss narrowed |
| EPS, basic (₹) | (0.50) | (0.69) | not comparable | (0.60) | not comparable |
| Net margin (%) | -734.6 | -1027.3 | -479.6 |
Consolidated
- Filed with BSE
- 28 May 2026, 15:40 IST
- Board meeting
- 13 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 May 2026, 15:40 IST
- Board meeting
- 13 May 2026
- Period
- 01 Jan 2026 to 31 Mar 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE